An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
-
- Laura VanBlargan
- Department of Medicine, Washington University School of Medicine
-
- John Errico
- Department of Pathology & Immunology, Washington University School of Medicine
-
- Peter Halfmann
- Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison
-
- Seth Zost
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Department of Pediatrics Vanderbilt University Medical Center
-
- James Crowe
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Department of Pediatrics Vanderbilt University Medical Center; Department of Pathology, and Microbiology and Immunology, Vanderbilt University Medical Center
-
- Lisa Purcell
- Vir Biotechnology
-
- Yoshihiro Kawaoka
- Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo
-
- Davide Corti
- Humabs BioMed SA, a subsidiary of Vir Biotechnology
-
- Daved Fremont
- Department of Pathology & Immunology, Washington University School of Medicine; Department of Molecular Microbiology, Washington University School of Medicine; Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine
-
- Michael Diamond
- Department of Medicine and Department of Pathology & Immunology and Department of Molecular Microbiology, Washington University School of Medicine; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine
説明
<title>Abstract</title> <p>The emergence of the highly-transmissible B.1.1.529 Omicron variant of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. Here, we tested a panel of anti-receptor binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 [Sotrovimab]), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Lilly (LY-CoV555 and LY-CoV016), and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use may lose efficacy against the B.1.1.529 Omicron variant.</p>
収録刊行物
-
- Nat Med
-
Nat Med 28 2021-12-27
Research Square Platform LLC
